← Eichor
Study identifier: NCT06988956 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Condition: Esophageal Squamous Cell Carcinoma  ·  Sponsor: The First Affiliated Hospital with Nanjing Medical University

PhasePhase 2
Planned participants95
Who can joinAll sexes, 75 Years to no upper limit
Healthy volunteersNo

About this study

investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaolin MM GE, PHD  ·  13951818797  ·  doctorsxl@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06988956